Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer
Authors
Keywords
-
Journal
CANCER BIOLOGY & THERAPY
Volume 16, Issue 3, Pages 438-449
Publisher
Informa UK Limited
Online
2015-05-28
DOI
10.1080/15384047.2014.1003005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
- (2014) S R McKeown BRITISH JOURNAL OF RADIOLOGY
- Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
- (2013) R Alvarez et al. BRITISH JOURNAL OF CANCER
- Microenvironment and tumor cell plasticity: An easy way out
- (2013) Maria Letizia Taddei et al. CANCER LETTERS
- Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer
- (2013) N. Awasthi et al. CARCINOGENESIS
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression
- (2012) Jean-Philippe Cosse et al. Anti-Cancer Agents in Medicinal Chemistry
- TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules
- (2012) Qian Liu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas
- (2012) M. Hidalgo et al. CLINICAL CANCER RESEARCH
- Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys
- (2011) Donald Jung et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer
- (2011) J. D. Sun et al. CLINICAL CANCER RESEARCH
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
- (2011) G. J. Weiss et al. CLINICAL CANCER RESEARCH
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Pathophysiological Response to Hypoxia — From the Molecular Mechanisms of Malady to Drug Discovery: Epigenetic Regulation of the Hypoxic Response via Hypoxia-Inducible Factor and Histone Modifying Enzymes
- (2011) Imari Mimura et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
- (2011) F. Meng et al. MOLECULAR CANCER THERAPEUTICS
- Toxicological Study and Efficacy of Blank and Paclitaxel-Loaded Lipid Nanocapsules After i.v. Administration in Mice
- (2010) José Hureaux et al. PHARMACEUTICAL RESEARCH
- Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs
- (2008) Jian-Xin Duan et al. JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now